Tuberculosis is one of the leading causes of development of Immune reconstitution inflammatory syndrome (IRIS) in HIV patients receiving antiretroviral therapy (ART). Objective: To determine the incidence of IRIS in HIV-TB coinfected patients, and to find out the possible risk factors associated with IRIS. Materials and Methods: Study commenced with 96 patients adhered to standard antitubercular therapy (ATT) and ART without defaultering, and followed up for six months. Result: The mean (± SD) CD4 count and CD4 percentage at baseline was 59.16 (± 24.63) per mm 3 and 4.59% (± 1.73) respectively. Only 18.75% developed IRIS after 57.05 (± 14.12) days of initiation of ART. Extrapulmonary tuberculosis was the most significant factor associated with IRIS (83.33%) than those without IRIS (44.87%) (p = 0.0032). Specifically, tubercular lymphadenitis (38.88%, p = 0.0364) and disseminated tuberculosis (33.33%, p = 0.0217) were significantly associated with IRIS. The other risk factors associated with appearance of IRIS were higher CD4 count (p = 0.0212) at three months after initiation of ART and increment of CD4 count (p = 0.0063) and CD4 percentage (p = 0.0016) during this period. The major manifestations of IRIS were fever (40%), followed by lymphadenitis (38%). The mortality rate in IRIS was not higher than those without IRIS. Conclusion: Patients with extrapulmonary tuberculosis, especially tubercular lymphadenitis, were more likely to develop IRIS and fever was associated in most of them. Higher increment of CD4 count may indicate development of IRIS in presence of new or worsening tuberculosis lesion.
INTRODUCTION
Human immunodeiciency virus (HIV) infection today is one of the major causes of mortality and morbidity globally. Association of tuberculosis (TB) coinfection with HIV poses greater therapeutic challenge. In developing nations, patients oten present late with advanced HIV infection along with diferent opportunistic infections, most commonly tuberculosis. 1 Tuberculosis in HIV-infected patients oten presents with diagnostic dificulties, with increased chance of negative sputum smear results, atypical chest X-ray findings, negative tuberculin skin test, lack of classical granuloma formation in late stage and also presence of more frequent extrapulmonary tuberculosis. With the advent of highly active antiretroviral therapy (HAART), incidence rate of immune reconstitution inlammatory syndrome (IRIS) also raised signiicantly. Classically IRIS is deined as "occurrence or manifestation of new or existing opportunistic infection within six weeks to six months ater initiation of antiretroviral therapy (ART), with associated increase in CD4 count". 2 Any opportunistic infection may present with IRIS though tuberculosis (TB) is the major cause. Other important manifestations include CMV retinitis, Pneumocystis jiroveci pneumonia, herpes simplex infection, varicella zoster virus infection, cryptococcal meningitis, hepatitis B, hepatitis C infection and even some auto-immune diseases. 3 he main features of IRIS with TB are increasing pneumonitis, development of pleural efusion, occurrence of new radiographic lesions, painful and enlarged lymphadenopathy, oten with discharging sinus, persistent fever, development of meningitis, expanding intracranial Este é um artigo Open Access sob a licença de CC BY-NC-ND space occupying lesions etc. 4, 5 It is hypothesized that pro-inlammatory cytokines produced excessively in response to systemic bacterial lipopolysacharide, nonspeciically act on latent mycobacterial antigens leading to clinical deterioration and paradoxical worsening of inlammatory responses. 6 In most of the cases, IRIS regress spontaneously without any signiicant mortality but sometimes it may cause worsening clinical scenario with respiratory failure and tracheal compression by enlarged lymph nodes resulting in death. It should be diferentiated from exacerbation of tuberculosis due to drug resistance or non-compliance, appearance of new tubercular lesion or other opportunistic infection due to advancement of HIV. Till date, there is lack of clinical data about occurrence of IRIS in HIV and TB coinfected patients in Indian population. herefore, we conducted a cross-sectional study in a tertiary care set-up to ind out prevalence and risk factors of IRIS in HIV-TB coinfected patients.
MATERIAL AND METHODS
Recently diagnosed HAART naive HIV-infected patients, who had clinical, radiological or microbiological evidence of active TB, were selected for our study. Inclusion criteria were as follows:
Recently diagnosed HIV positive by ELISA method. (According to NACO guideline, a symptomatic suspected HIV-infected person is diagnosed HIV positive when the serum sample is reactive with at least two out of three different ELISA kit). 2 Patient having active tuberculosis diagnosed by clinical features, radiological appearances, presence of granuloma in aspiration material, or microscopy and/or culture positive acid-fast bacilli (AFB).
Receiving antitubercular therapy (ATT) from Revised National Tuberculosis Control Programme (RNTCP).
Started ART after 15 days of ATT as per protocol followed in the institution.
All the patients were followed up for the period of six months. The patients with non-compliance with either ATT or ART during the follow-up period were excluded from the study. The diagnosis of IRIS was done using the pre-set criteria as follows:
The patient had to be on ART with rising CD4 count. Prior to starting ART, the patient must have documented radiological, histological or microbiologically confirmed tuberculosis.
Prior to starting ART, patient must have improvement of tuberculosis by antitubercular therapy.
Following initiation of ART, the patients must have appearance of new symptoms or re-appearance of previous symptoms.
The patients must have spontaneous resolution of symptoms with continuation of same treatment.
Our primary objective was to determine the incidence of IRIS in HIV-TB coinfected patients. Secondarily we tried to ind out the possible risk factors for emergence of IRIS. he patients were divided into two groups according to development of IRIS or not. he demographic, clinical features, site of tuberculosis, presence of other opportunistic infection, baseline and follow-up CD4 count were measured and compared between the two groups. he statistical analysis was done, using chi-square test and Student's t test using SPSS ver-16 to determine the signiicance of the variables. A p-value < 0.05 was taken to be statistically signiicant. A total of 96 patients, who were attending Medicine outdoor and indoor of Medical College Kolkata from May 2009 to April 2010, who met the eligibility criteria, were included in this study. he study was approved by the institutional ethical committee. he necessary informed consent was taken from all the patients.
RESULTS
Out of 96 patients sufering from both HIV and tuberculosis, 84 (87.5%) of them male, only 18 (18.75%) patients developed IRIS (Table 1) . he initial mean (± SD) CD4 count of these patients was 59.16 (± 24.63) per mm 3 and initial mean CD4 percentage was 4.59% (± 1.73). he baseline parameters of the patients developing IRIS and those who did not develop IRIS were compared (Table 1) . he male:female ratios of both groups were comparable. here was no signiicant diference between the two groups in respect of mode of transmission of HIV. But the distribution of tuberculosis is strikingly diferent between the two groups. hose, who developed IRIS had signiicantly higher incidence of extrapulmonary tuberculosis (83.33%) than those who did not develop IRIS (44.87%) (p = 0.0032). Of the various forms of extrapulmonary tuberculosis in IRIS positive patients, most had tubercular lymphadenitis (38.88%). None of the IRIS positive patient had CNS tuberculosis. he initial CD4 count in both groups were comparable, but the patients with IRIS experienced signiicantly higher increments of mean CD4 count (45. ) (p = 0.0212). he symptoms during development of IRIS are described in Table 2 and Table 3 . Among the various systemic symptoms developed with IRIS, fever was predominant involving 40% patients of IRIS. he second most common symptom was generalized lymphadenopathy (38%). he incidence of lare up of pulmonary tuberculosis was 18%, while that of abdominal tuberculosis manifested by tubercular ascites and enlargement of abdominal lymph nodes was 27 percent. Only ive patients required hospital admission for the severe manifestation of IRIS and intra-venous hydrocortisone was administered as a life-saving measure. Two of them died in hospital. ART was continued in all of the patients. he patients who did not develop IRIS mostly improved clinically with resolution of their symptoms. Only 11 of 78 non-IRIS patients (14.1%) had clinical deterioration, of which three had pulmonary tuberculosis, and the others had extrapulmonary tuberculosis. hese patients did not show any initial improvement. he mortality rates in both TB-IRIS and non-IRIS groups were comparable. he cause of death in one of the two persons sufering from IRIS was the compression of trachea by enlarged cervical lymph nodes, while the other died due to disseminated tuberculosis leading to multi-organ failure. Out of seven non-IRIS patients who died during the study, three had CNS tuberculosis, mostly meningitis, and four had disseminated tuberculosis. None of the patient with pulmonary tuberculosis died during the study. he mean duration of development of IRIS ater initiation of ART was 57.05 (± 14.12) days (Table 2) . he ART followed was according to the NACO guideline and was similar in both groups. ART was started in all patients ater 15 days of ATT. De, Sarkar, Phaujdar, et al.
DISCUSSION
he incidence of IRIS varies throughout the world. In pre-HAART era, incidence of IRIS in developed countries was reported to be about 36%. 7 In developing countries, due to higher prevalence of tuberculosis, the incidence of IRIS is also higher, though remains largely under reported. he incidence in developing countries ranges from 11% to 43%, whereas in India it was reported as 8%. 6, 8 In our study, incidence of TB-IRIS was 18.75%. As HAART is now widely available in India, the incidence of IRIS is likely to be increasing. he IRIS appears mostly within irst three months of initiating ART. In our study the mean duration of appearance of IRIS was 57.05 days. he early appearance of IRIS may be due to early initiation of ART, ater 15 days of ATT, in all patients. Other studies from developing countries like Brazil also documented similar result. 9 Shelburne et al. 10 showed that IRIS is more likely to develop earlier if HAART is initiated earlier.
Most of the IRIS patients experienced an exacerbation of extrapulmonary tuberculosis, tubercular lymphadenitis being most common. Signiicantly 27% of the patients presented with intra-abdominal laring up of tuberculosis. Various previous studies also showed similar result though occurrence of intra-abdominal tuberculosis was not high. [11] [12] [13] his highlights that one must look out for the enlargement of abdominal lymph nodes as a marker of IRIS. Interestingly, in our study, none had CNS tubercular manifestation. his may be because CNS involvement in TB-IRIS usually occurs late with median interval being 5-10 months.
14 he risk factor emerged from the study was presence of extrapulmonary tuberculosis, of which tubercular lymphadenitis and disseminated tuberculosis predominates. hese indings corroborates with the indings of previous western studies, though they did not show disseminated tuberculosis as a risk factor. 15 his may be due to the fact, that exposure to high load of mycobacterium and their interaction with the immune system in disseminated form of tuberculosis increases the risk of IRIS. 16 he baseline CD4 count was not a risk factor for emergence of IRIS. Although previous studies, including those from diferent developing countries with high prevalence of HIV, postulated that CD4 counts less than 100 per mm 3 are associated with increased incidence of IRIS, this was not present in our study. 9, 17 Rather, the increase in absolute as well as percentage of CD4 count was signiicantly higher in IRIS group of patients than the other. Similar result was shown by Breton G et al. 12 his may be due to the inherent pathophysiology of IRIS development. With the initiation of ART, there is partial restoration of immune response, which causes increase in CD4 count. As IRIS occurs due to excessive efect of various inlammatory mediators liberated from activated lymphocytes, so increment of CD4 count is related with occurrence of IRIS and it may act as a surrogate marker of development of IRIS, though more detailed studies need to be done to know the actual predictive value. The major limitation of the study was exclusion of subclinical tuberculosis patients who may develop IRIS after initiation of ART. Also all the patients were given standard ATT and ART, so effect of variation of therapy with emergence of IRIS was not evaluated. In addition, because ART was started after 15 days of ATT in all patients, any effect of delay of ART with appearance of IRIS could not be studied. All the patients recruited in the study were in advanced HIV. Further study is needed to know the variation of incidence of IRIS at different stages of HIV. Although most of our patients recovered spontaneously without requiring any deviation from their treatment protocol, large prospective study will guide us about proper management of IRIS.
CONCLUSION
In conclusion, IRIS in HIV-TB coinfected patients is an important entity, 12% of the patients developed IRIS in our study within two months of starting ART. Patients with extrapulmonary tuberculosis, especially tubercular lymphadenitis are more prone to develop IRIS. Fever is associated in most of these patients. Higher increment of CD4 count may give warning for development of IRIS in presence of new or worsening tuberculosis lesion.
